Citi Downgrades PTC Therapeutics (PTCT) to Neutral
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Price: $67.37 -0.3%
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 14 | New: 59
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 14 | New: 59
Join SI Premium – FREE
Citi analyst Joel Beatty downgraded PTC Therapeutics (NASDAQ: PTCT) from Buy to Neutral with a price target of $67.00 (from $67.00).
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $53.89 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Downgrades Gencor Industries (GENC) to Hold
- HSBC Downgrades Amgen (AMGN) to Hold
- Jefferies Downgrades Harworth Group PLC (HWG:LN) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
